FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017537892> ?p ?o ?g. }

• W2017537892 endingPage "140" @default.
• W2017537892 startingPage "132" @default.
• W2017537892 abstract "Gemcitabine is a deoxycytidine analog used in the treatment of various solid tumors. However, tumors often develop resistances over time, which becomes a major issue for most gemcitabine-related chemotherapies. In the present study, a previously reported stearoyl gemcitabine nanoparticle formulation (GemC18-NPs) was evaluated for its ability to overcome gemcitabine resistance. In the wild type CCRF-CEM human leukemia cells, the IC50 value of GemC18-NPs was 9.5-fold greater than that of gemcitabine hydrochloride (HCl). However, in the CCRF-CEM-AraC-8C cells that are deficient in the human equilibrative nucleoside transporter-1, the IC50 of GemC18-NPs was only 3.4-fold greater than that in the parent CCRF-CEM cells, whereas the IC50 of gemcitabine HCl was 471-fold greater than that in the parent CCRF-CEM cells. The GemC18-NPs were also more cytotoxic than gemcitabine HCl in the deoxycytidine kinase deficient (CCRF-CEM/dCK−/−) tumor cells. Similar to gemcitabine HCl, GemC18-NPs induced apoptosis through caspase activation. Another gemcitabine-resistant tumor cell line, TC-1-GR, was developed in our laboratory. In the TC-1-GR cells, the IC50 of GemC18-NPs was only 5% of that of gemcitabine HCl. Importantly, GemC18-NPs effectively controlled the growth of gemcitabine resistant TC-1-GR tumors in mice, whereas the molar equivalent dose of gemcitabine HCl did not show any activity against the growth of the TC-1-GR tumors. Proteomics analysis revealed that the TC-1-GR cells over-expressed ribonucleotide reductase M1, which was likely the cause of the acquired gemcitabine resistance in the TC-1-GR cells. To our best knowledge, this represents the first report demonstrating that a nanoparticle formulation of gemcitabine overcomes gemcitabine resistance related to ribonucleotide reductase M1 over-expression." @default.
• W2017537892 created "2016-06-24" @default.
• W2017537892 creator A5013190172 @default.
• W2017537892 creator A5020637830 @default.
• W2017537892 creator A5042647297 @default.
• W2017537892 creator A5050114813 @default.
• W2017537892 creator A5087576156 @default.
• W2017537892 date "2012-01-01" @default.
• W2017537892 modified "2023-09-27" @default.
• W2017537892 title "Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1" @default.
• W2017537892 cites W113740469 @default.
• W2017537892 cites W1985268469 @default.
• W2017537892 cites W2012432138 @default.
• W2017537892 cites W2012691926 @default.
• W2017537892 cites W2020481162 @default.
• W2017537892 cites W2022237067 @default.
• W2017537892 cites W2028331391 @default.
• W2017537892 cites W2028937842 @default.
• W2017537892 cites W2040964625 @default.
• W2017537892 cites W2041727257 @default.
• W2017537892 cites W2061876263 @default.
• W2017537892 cites W2063226474 @default.
• W2017537892 cites W2066755265 @default.
• W2017537892 cites W2068581230 @default.
• W2017537892 cites W2076583198 @default.
• W2017537892 cites W2077945404 @default.
• W2017537892 cites W2092057012 @default.
• W2017537892 cites W2095287544 @default.
• W2017537892 cites W2096289704 @default.
• W2017537892 cites W2102449174 @default.
• W2017537892 cites W2103832597 @default.
• W2017537892 cites W2107565528 @default.
• W2017537892 cites W2123494134 @default.
• W2017537892 cites W2126107019 @default.
• W2017537892 cites W2129793148 @default.
• W2017537892 cites W2133436228 @default.
• W2017537892 cites W2133478112 @default.
• W2017537892 cites W2140095109 @default.
• W2017537892 cites W2142485373 @default.
• W2017537892 cites W2144321662 @default.
• W2017537892 cites W2149372254 @default.
• W2017537892 cites W2152832279 @default.
• W2017537892 cites W2161254114 @default.
• W2017537892 cites W2161769699 @default.
• W2017537892 cites W2164529446 @default.
• W2017537892 cites W2270490184 @default.
• W2017537892 cites W271570111 @default.
• W2017537892 doi "https://doi.org/10.1016/j.jconrel.2011.08.004" @default.
• W2017537892 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3236813" @default.
• W2017537892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21851843" @default.
• W2017537892 hasPublicationYear "2012" @default.
• W2017537892 type Work @default.
• W2017537892 sameAs 2017537892 @default.
• W2017537892 citedByCount "52" @default.
• W2017537892 countsByYear W20175378922012 @default.
• W2017537892 countsByYear W20175378922013 @default.
• W2017537892 countsByYear W20175378922014 @default.
• W2017537892 countsByYear W20175378922015 @default.
• W2017537892 countsByYear W20175378922016 @default.
• W2017537892 countsByYear W20175378922017 @default.
• W2017537892 countsByYear W20175378922018 @default.
• W2017537892 countsByYear W20175378922019 @default.
• W2017537892 countsByYear W20175378922020 @default.
• W2017537892 countsByYear W20175378922021 @default.
• W2017537892 countsByYear W20175378922022 @default.
• W2017537892 countsByYear W20175378922023 @default.
• W2017537892 crossrefType "journal-article" @default.
• W2017537892 hasAuthorship W2017537892A5013190172 @default.
• W2017537892 hasAuthorship W2017537892A5020637830 @default.
• W2017537892 hasAuthorship W2017537892A5042647297 @default.
• W2017537892 hasAuthorship W2017537892A5050114813 @default.
• W2017537892 hasAuthorship W2017537892A5087576156 @default.
• W2017537892 hasBestOaLocation W20175378922 @default.
• W2017537892 hasConcept C104292427 @default.
• W2017537892 hasConcept C104317684 @default.
• W2017537892 hasConcept C126322002 @default.
• W2017537892 hasConcept C185592680 @default.
• W2017537892 hasConcept C190283241 @default.
• W2017537892 hasConcept C202751555 @default.
• W2017537892 hasConcept C2776694085 @default.
• W2017537892 hasConcept C2777752497 @default.
• W2017537892 hasConcept C2777844706 @default.
• W2017537892 hasConcept C2779268695 @default.
• W2017537892 hasConcept C2780258809 @default.
• W2017537892 hasConcept C4710235 @default.
• W2017537892 hasConcept C502942594 @default.
• W2017537892 hasConcept C54355233 @default.
• W2017537892 hasConcept C55493867 @default.
• W2017537892 hasConcept C71924100 @default.
• W2017537892 hasConcept C81885089 @default.
• W2017537892 hasConcept C86803240 @default.
• W2017537892 hasConcept C98274493 @default.
• W2017537892 hasConceptScore W2017537892C104292427 @default.
• W2017537892 hasConceptScore W2017537892C104317684 @default.
• W2017537892 hasConceptScore W2017537892C126322002 @default.
• W2017537892 hasConceptScore W2017537892C185592680 @default.
• W2017537892 hasConceptScore W2017537892C190283241 @default.
• W2017537892 hasConceptScore W2017537892C202751555 @default.

• next